Surakameth Mahasirimongkol

Dr. Surakameth Mahasirimongkol


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2012 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
HYHideki Yanai
Hideki Yanai
TMTaisei Mushiroda
Taisei Mushiroda
WPWatoo Promphittayarat
Watoo Promphittayarat
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
KTKatsushi Tokunaga
Katsushi Tokunaga
Tuberculosis (TB) is one of the most devastating chronic infectious diseases, but the role of host genetics in disease development after infection in this disease remains unidentified. Genome-wide association studies (GWASs) in Thais and Japanese were carried out and separately analyzed, attempted replication, then, combined by meta-analysis were not yielding any convincing association evidences; these results suggested that moderate to high effect-size genetic risks are not existed for TB per se. Because of failure in replication attempt of the top 50 single-nucleotide polymorphisms (SNPs) identified form meta-analysis data, we empirically split TB cases into young TB case/control data sets (GWAS-Tyoung=137/295 and GWAS-Jyoung=60/249) and old TB case/control data sets (GWAS-Told=300/295 and GWAS-Jold=123/685), re-analyzed GWAS based on age-stratified data and replicated the significant findings in two independent replication samples (young TB; Rep-Tyoung=155/249, Rep-Jyoung=41/462 and old TB; Rep-Told=212/187, Rep-Jold=71/619). GWAS and replication studies conducted in young TB identified at-risk locus in 20q12. Although the locus is located in inter-genic region, the nearest genes (HSPEP1-MAFB) from this locus are promising candidates for TB susceptibility. This locus was also associated with anti-TNF responsiveness, drug with increased susceptibility for TB. Moreover, eight SNPs in an old TB meta-analysis and six SNPs in young TB meta-analysis provided replication evidences but did not survive genome-wide significance.These findings suggest that host genetic risks for TB are affected by age at onset of TB, and this approach may accelerate the identification of the major host factors that affect TB in human populations.

7 September 2017 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
YOYosuke Omae
Yosuke Omae
LTLicht Toyo-Oka
Licht Toyo-Oka
HYHideki Yanai
Hideki Yanai
SNSupalert Nedsuwan
Supalert Nedsuwan
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
Tuberculosis (TB) is known to be affected by host genetic factors. We reported a specific genetic risk factor through a genome-wide association study (GWAS) that focused on young age onset TB. In this study, we further focused on the heterogeneity of Mycobacterium tuberculosis (M. tb) lineages and assessed its possible interaction with age at onset on host genetic factors. We identified the pathogen lineage in 686 Thai TB cases and GWAS stratified by both infected pathogen lineage information and age at onset revealed a genome-wide significant association of one single-nucleotide polymorphism (SNP) on chromosome 1p13, which was specifically associated with non-Beijing lineage-infected old age onset cases (P=2.54E-08, OR=1.74 (95% CI=1.43–2.12)), when we compared them to the population-matched healthy controls. This SNP locates near the CD53 gene, which encodes a leukocyte surface glycoprotein. Interestingly, the expression of CD53 was also correlated with the patients’ active TB status. This is the first report of a pathogen lineage-based genome-wide association study. The results suggested that host genetic risk in TB is depended upon the pathogen genetic background and demonstrate the importance of analyzing the interaction between host and pathogen genomes in TB.

23 November 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PIPORNTIP INTAPIBOON
PORNTIP INTAPIBOON
PSPurilap Seepathomnarong
Purilap Seepathomnarong
JOJomkwan Ongarj
Jomkwan Ongarj
SSSmonrapat Surasombatpattana
Smonrapat Surasombatpattana
SUSupattra Uppanisakorn
Supattra Uppanisakorn
Nawamin PinpathomratNawamin Pinpathomrat
Nawamin Pinpathomrat
Effective vaccine coverage is urgently needed to tackle the COVID-19 pandemic. Inactivated vaccines have been introduced in many countries for emergency usage, but have only provided limited protection. Heterologous vaccination is a promising strategy to maximise vaccine immunogenicity. Here, we conducted a phase I, randomised control trial to observe the safety and immunogenicity after an intradermal boost, using a fractional dosage (1:5) of BNT162b2 mRNA vaccine in healthy participants in Songkhla, Thailand. In total, 91 volunteers who had been administered with two doses of inactivated SARS-CoV-2 (CoronaVac) were recruited into the study, and then randomised (1:1:1) to received different regimens of the third dose. An intramuscular booster with a full dose of BNT162b2 was included as a conventional control, and a half dose group was included as reciprocal comparator. Both, immediate and delayed adverse events following immunisation (AEFI) were monitored. Humoral and cellular immune responses were examined to observe the booster effects. The intradermal booster provided significantly fewer systemic side effects, from 70% down to 19.4% (p < 0.001); however, they were comparable to local reactions with the conventional intramuscular booster. In the intradermal group after receiving only one fifth of the conventional dosage, serum Anti-RBD IgG was halved compared to the full dose of an intramuscular injection. However, the neutralising function against the Delta strain remained intact. T cell responses were also less effective in the intradermal group compared to the intramuscular booster. Together, the intradermal booster, using a fractional dose of BNT162b2, can reduce systemic reactions and provides a good level and function of antibody responses compared to the conventional booster. This favourable intradermal boosting strategy provides a suitable alternative for vaccines and effective vaccine management to increase the coverage during the vaccine shortage.

24 August 2016 in Epilepsia
Verified
Journal Article
Closed access
PDF file
WMWiparat Manuyakorn
Wiparat Manuyakorn
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol
PLPlernpit Likkasittipan
Plernpit Likkasittipan
WKWasu Kamchaisatian
Wasu Kamchaisatian
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
SBSuwat Benjaponpitak
Suwat Benjaponpitak

1 May 2020 in Epilepsy Research
Verified
Journal Article
Closed access
WMWiparat Manuyakorn
Wiparat Manuyakorn
PLPlernpit Likkasittipan
Plernpit Likkasittipan
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
SSSupharat Suvichapanich
Supharat Suvichapanich
WIWimala Inunchot
Wimala Inunchot
SMSurakameth Mahasirimongkol
Surakameth Mahasirimongkol

1 August 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SSSupharat Suvichapanich
Supharat Suvichapanich
SWSukanya Wattanapokayakit
Sukanya Wattanapokayakit
TMTaisei Mushiroda
Taisei Mushiroda
HYHideki Yanai
Hideki Yanai
CCCharoen Chuchottawon
Charoen Chuchottawon
KTKatsushi Tokunaga
Katsushi Tokunaga
Antituberculosis drug-induced liver injury (ATDILI) is a common side effect leading to tuberculosis (TB) treatment disruption. The mechanism of the disease remains poorly understood. We conducted a genomewide association study (GWAS) to investigate all possible genetic factors of ATDILI in Thai patients. This study was carried out in Thai TB patients, including 79 ATDILI cases and 239 tolerant controls from our network hospitals in Thailand. Nearly 1 million single-nucleotide polymorphisms (SNPs) were genotyped across the whole genome using an Illumina OmniExpress Exome BeadChip array. In the discovery stage, we identified strong association signals on chromosome 8 originating from the N-acetyltransferase (NAT2) region. The A allele of rs1495741, the top SNP in the intergenic region of NAT2 and PSD3 (14 kb from NAT2), was significantly associated with ATDILI (recessive model, odds ratio of 6.01 [95% confidence interval, 3.42 to 10.57]; P = 6.86E−11). This particular SNP was reported as a tag SNP for NAT2 inferred phenotypes. The AA, AG, and GG genotypes represented NAT2 slow acetylators, intermediate acetylators, and fast acetylators, respectively. The tag SNP genotypes demonstrated a concordance rate of 94.98% with NAT2 acetylator phenotypes. This GWAS shows that NAT2 is the most important risk factor for ATDILI in the Thai population.